Seong-Chul Kim
Direttore/Membro del Consiglio presso KPS CORPORATION
Patrimonio netto: 3 M $ in data 31/05/2024
Posizioni attive di Seong-Chul Kim
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| KPS CORPORATION | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Seong-Chul Kim
Precedenti posizioni note di Seong-Chul Kim
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
LSK Investment Co. Ltd.
 LSK Investment Co. Ltd. Investment ManagersFinance LSK Investment Co. Ltd. (LSK Investment), a private equity & venture capital subsidiary of HLB Life Science Co Ltd., was founded in 2016. The firm is headquartered in Seoul, South Korea. | Amministratore Delegato | 11/04/2016 | 31/12/2018 |
Elevar Therapeutics, Inc.
 Elevar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elevar Therapeutics, Inc. engages in the provision of biopharmaceutical services. It offers Rivoceranib, a small-molecule angiogenesis inhibitor in gastric cancer that use in the growth and proliferation in cancer cells. The company was founded by Sung Chul Kim and Soo Whan Choi in 2005 and is headquartered in Salt Lake City, UT. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - | |
| Fondatore | 01/01/2005 | - | |
| Presidente | 01/01/2005 | - | |
| HLB CO., LTD. | Direttore/Membro del Consiglio | - | - |
| Corporate Officer/Principal | - | - |
Statistiche
Distribuzione geografica
| Corea del Sud | 4 |
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 3 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 3 |
| Finance | 2 |
| Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| HLB CO., LTD. | Health Technology |
| KPS CORPORATION | Electronic Technology |
| Aziende private | 2 |
|---|---|
Elevar Therapeutics, Inc.
Elevar Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elevar Therapeutics, Inc. engages in the provision of biopharmaceutical services. It offers Rivoceranib, a small-molecule angiogenesis inhibitor in gastric cancer that use in the growth and proliferation in cancer cells. The company was founded by Sung Chul Kim and Soo Whan Choi in 2005 and is headquartered in Salt Lake City, UT. | Health Technology |
LSK Investment Co. Ltd.
LSK Investment Co. Ltd. Investment ManagersFinance LSK Investment Co. Ltd. (LSK Investment), a private equity & venture capital subsidiary of HLB Life Science Co Ltd., was founded in 2016. The firm is headquartered in Seoul, South Korea. | Finance |
- Borsa valori
- Insiders
- Seong-Chul Kim
- Esperienza
